The field of acute myeloid leukaemia (AML) diagnostics, initially based solely on morphological assessment, has integrated more and more disciplines. Today, state-of-the-art AML diagnostics relies on cytomorphology, cytochemistry, immunophenotyping, cytogenetics and molecular genetics. Only the integration of all of these methods allows for a comprehensive and complementary characterisation of each case, which is prerequisite for optimal AML diagnosis and management. Here, we will review why multidisciplinary diagnostics is mandatory today and will gain even more importance in the future, especially in the context of precision medicine. We will discuss ideas and strategies that are likely to shape and improve multidisciplinary diagnostics in AML and may even overcome some of today's gold standards. This includes recent technical advances that provide genome-wide molecular insights. The enormous amount of data obtained by these latter techniques represents a great challenge, but also a unique chance. We will reflect on how this increase in knowledge can be incorporated into the routine to pave the way for personalised medicine in AML.

中文翻译：

---

急性髓系白血病综合诊断的力量和潜力。


急性髓系白血病（AML）诊断领域最初仅基于形态学评估，现已整合了越来越多的学科。如今，最先进的 AML 诊断依赖于细胞形态学、细胞化学、免疫表型、细胞遗传学和分子遗传学。只有整合所有这些方法才能对每个病例​​进行全面和互补的表征，这是最佳 AML 诊断和管理的先决条件。在这里，我们将回顾为什么多学科诊断在今天是强制性的，并且在未来将变得更加重要，特别是在精准医学的背景下。我们将讨论可能塑造和改进 AML 多学科诊断的想法和策略，甚至可能克服当今的一些黄金标准。这包括提供全基因组分子见解的最新技术进步。通过后一种技术获得的大量数据代表着巨大的挑战，但也是一个独特的机会。我们将思考如何将这种知识的增长融入到常规治疗中，为 AML 的个性化医疗铺平道路。